@article{3106053,
    title = "IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy",
    author = "Humbert, M. and Bousquet, J. and Bachert, C. and Palomares, O. and Pfister, P. and Kottakis, I. and Jaumont, X. and Thomsen, S.F. and Papadopoulos, N.G.",
    journal = "The Journal of Allergy and Clinical Immunology: In Practice",
    year = "2019",
    volume = "7",
    number = "5",
    pages = "1418-1429",
    publisher = "American Academy of Allergy, Asthma and Immunology",
    issn = "2213-2198",
    doi = "10.1016/j.jaip.2019.02.030",
    keywords = "immunoglobulin E;  omalizumab;  antiallergic agent;  immunoglobulin E;  omalizumab, allergic asthma;  allergic bronchopulmonary aspergillosis;  allergic rhinitis;  antigen presenting cell;  antigen specificity;  atopic dermatitis;  chronic rhinosinusitis;  disease association;  disease burden;  disease control;  disease registry;  disease severity;  drug efficacy;  drug safety;  drug sensitization;  food allergy;  human;  multiple chronic conditions;  nose polyp;  Review;  rhinoconjunctivitis;  social status;  Th2 cell;  vernal conjunctivitis;  visual analog scale;  allergic bronchopulmonary aspergillosis;  allergic conjunctivitis;  allergic rhinitis;  asthma;  atopic dermatitis;  chronic disease;  food allergy;  immediate type hypersensitivity;  immunology;  multiple chronic conditions;  nose polyp;  sinusitis, Anti-Allergic Agents;  Aspergillosis, Allergic Bronchopulmonary;  Asthma;  Chronic Disease;  Conjunctivitis, Allergic;  Dermatitis, Atopic;  Food Hypersensitivity;  Humans;  Hypersensitivity, Immediate;  Immunoglobulin E;  Multimorbidity;  Nasal Polyps;  Omalizumab;  Rhinitis, Allergic;  Sinusitis",
    abstract = "Allergic asthma often coexists with different pathological conditions, called multimorbidities, that are mostly of allergic nature and share a common underlying inflammatory pathophysiological mechanism. Multimorbidities of allergic asthma may influence asthma control, its severity, and patients' response to treatment, and contribute to the overall socioeconomic burden of the disease. Immunoglobulin E (IgE) is known to play a central role in the pathogenesis of various allergic diseases, including asthma. Thus, IgE-mediated immunologic pathways present an attractive target for intervention in asthma and multimorbidities. In this review, we discuss the most frequently reported IgE-mediated multimorbidities in allergic asthma, including allergic rhinitis, rhinoconjunctivitis, atopic dermatitis, vernal keratoconjunctivitis, chronic rhinosinusitis with nasal polyps, food allergies, and allergic bronchopulmonary aspergillosis. Omalizumab is a recombinant humanized monoclonal antibody against IgE and has been in use to treat allergic asthma for more than a decade. We comprehensively review the clinical evidence for omalizumab in the treatment of the aforementioned multimorbidities in allergic asthma. © 2018 The Authors"
}